

ORCA - Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:https://orca.cardiff.ac.uk/id/eprint/98072/

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Li, Jia V., Swann, Jonathan and Marchesi, Julian Roberto 2017. Biology of the microbiome 2: metabolic role. Gastroenterology Clinics of North America 46 (1) , pp. 37-47. 10.1016/j.gtc.2016.09.006

Publishers page: http://dx.doi.org/10.1016/j.gtc.2016.09.006

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 Biology of the Microbiome 2. Metabolic role.

2 Jia V. Li^{*1} PhD, Jonathan Swann^{*1} PhD and Julian R. Marchesi^{1,2,3 &4}PhD

3 Address

- ¹Section of Biomolecular Medicine, Division of Computational & Systems Medicine,
 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, UK.
- ²Divison of Digestive Diseases, Department of Surgery & Cancer, Faculty of Medicine,
 Imperial College London, UK.
- ³Centre for Digestive and Gut Health, Department of Surgery & Cancer, Imperial College
 London, UK.
- ⁴School of Biosciences, Cardiff University, Museum Avenue, Cardiff, UK.

11 Key Points

12 Microbiome, metabonome, 'omic approaches, metabolic interactions

13 ***Both these authors contributed equally to this manuscript.**

Synopsis: The human microbiome is a new frontier in biology and one that is helping to define what it is to be human. Recently we have begun to understand that the "communication" between the host and its microbiome is via a metabolic super-highway. By interrogating and understanding the molecules involved we may start to know who the main players are, how we can modulate them and mechanisms of health and disease.

19 **Keywords:** Metabonome, microbiome, mass spectrometry, NMR, multi-variate data.

21 Introduction

22 Understanding mammalian biology has for the best part of 100 years been focused on trying 23 to model how this system interacts with the environment. Since the discovery that DNA contains all the necessary information to recreate a new living organism and coupled with the 24 revolution in gene sequencing, this focus turned to try to understand how host's genome 25 interacts with its environment to influence the balance between health and disease. A 26 27 significant component of this body of work has been focused on the role of microbial pathogens in driving disease phenotypes. However, there is a dearth of information which 28 considers that the microbes colonising the various niches of the human body may actually 29 have co-evolved with the host and provide essential functions not found in the host's genome. 30 The role of mammalian microbiome is revealed, in extremis, when animals are reared in a 31 sterile environment ^{1,2} and thus do not develop in the presence of a microbiota. The absence 32 of the microbiome has been shown to influence a very wide and disparate range of 33 physiological parameters, including cardiac size and output ³, response to anaesthesia ⁴ and 34 35 many other features of the mature mammalian system ⁵. While we can see a fundamental role for the microbiome in the development of a mature host we are left with a dearth of 36 mechanisms by which this process is driven. 37

38 Why do we need to know what metabolites are made?

The history of microbiology has been predominantly focused on understanding the role that 39 pathogens play in disease, and this goes back to the time of Robert Koch and Louis Pasteur. 40 41 However, in the last 15 years there has been a slow, but inexorable move towards understanding how the commensal and mutualistic members of the human microbiome also 42 contribute to host health and disease initiation. In the last five years this interest in the 43 microbiome has really expanded at an exponential rate. However, we cannot treat these 44 organisms in a similar fashion to pathogenic microbes, since they have not evolved specific 45 strategies to invade, colonise and reproduce in a hostile environment. Many of the functions 46

47 and features that they possess, and on which we rely, do not conform to the virulence model that we have used to describe and understand pathogens. Many of the functions are actually 48 part of that everyday metabolism of these organisms and as such cannot be considered as 49 50 virulence factors. For example, for many anaerobic bacteria which colonise the large intestine 51 the ability to ferment simple molecules, to extract energy from them, results in a wide range of 52 metabolites which are bioactive and interact with a wide range of receptors within the host. 53 Thus the communication between this diverse set of organisms and its host is predominantly 54 via a metabolite super-highway. Thus in order to understand this communication we need to 55 be able to characterise the wide array of metabolites that the bacteria produce in response to 56 the environment in which they find themselves and understand how the host responds to these metabolites based on the genes that they have. 57

58 How do assess them and what can we assess – NMR and MS, what samples?

59 Microbial metabolites are typically present in faeces, luminal contents and blood, particularly 60 the hepatic portal vein blood, whilst host-microbial co-metabolites are present more commonly 61 in circulating blood and urine. Metabolic profiling approaches are increasingly used to study 62 metabolic function of the gut microbiota. The practical implementation of metabolic profiling 63 includes five steps: (1) sample collection and preparation; (2) biochemical composition 64 analyses; (3) data analysis and integration (e.g. statistically correlating metabolic and 65 microbial data); (4) biomarker recovery and identification; and (5) validation and application.

Urine and blood plasma or serum collection is straightforward, whereas obtaining faecal samples is more challenging and rarely done at outpatient clinics. Moreover, faecal samples are complex in nature since they contain microbial and mammalian cells and food residues, in which the biological and chemical processes continue during post-voiding and sample handling. Hence, storing samples at a lower temperature and immediate sample processing reduce the variation induced by sample handling. Standard operating procedures for biofluid collection and the effects of various handling conditions on the biochemical composition have

previously been reported ⁶⁻⁸. Analytical platforms, including nuclear magnetic resonance (NMR) 73 spectroscopy and mass spectrometry (MS), are commonly used in metabolic profiling and can 74 detect a wide range of microbial metabolites and host-microbial co-metabolites. NMR 75 spectroscopy is a robust analytical platform with high reproducibility and it generates the most 76 77 easily accessible and comprehensive information on metabolite structures. Although the sensitivity of NMR spectroscopy is less than mass spectrometry, it is non-destructive and 78 79 requires minimum sample preparation. A single proton (¹H) NMR experiment using a 600 MHz NMR spectrometer takes about 5-10 minutes and can detect a wide range of metabolites 80 including amino acids, fatty acids, phenols, indole and other organic acids containing protons 81 82 at low-micromolar levels. Therefore, it serves as the first choice for global profiling. Mass 83 spectrometry provide complementary molecular information (e.g. molecular mass) and it is 84 much more sensitive than NMR spectroscopy, but often requires pre-separation techniques 85 such as liquid chromatography (LC) and gas chromatography (GC). Depending on the 86 metabolites of the interest, different methods can be employed in liquid chromatography to 87 focus on subsets of molecules. For example, reversed phase chromatography (RP-LC) is used 88 to study non-polar compounds whereas hydrophilic interaction liquid chromatography (HILIC) 89 is used for detecting polar compounds. Both RP-LC-MS and HILIC-MS are routinely used to 90 analyse the same sample sets to achieve wider metabolite coverage. GC-MS is also a 91 sensitive tool in metabolic profiling and commonly used to quantify short chain fatty acids. 92 However, the drawback of GC-MS is that it requires derivatisation of the samples, a long sample preparation procedure, and only volatile compounds or compounds that are volatile 93 after derivatisation can be detected. The main metabolic profiling platforms and their strengths 94 and limitations have been summarised by Holmes et al. 2015 9. Detailed experimental 95 protocols for global metabolic profiling ¹⁰⁻¹² and bile acid profiling ¹³ have been published. 96

All of these analytical tools generate signal-rich data, which requires multivariate statistical
analyses to extract useful information from the datasets. Multivariate data analysis methods,
typically including principal component analysis (PCA), orthogonal projections to latent

100 structures-discriminant analysis (O-PLS-DA) and random forest, provide easy visualisation of the metabolic similarities and differences between the samples or spectral data. O-PLS 101 regression analysis is also used to statistically correlate metabolic data with other types of 102 103 datasets, such as body weight, histological scores, bacterial counts generated from 16S rRNA 104 gene based sequencing platform, cytokines, toxicity, see Fig 1 as an example. Such 105 correlation analysis between metabolic and microbial datasets allows further insight on 106 metabolites that are likely to be associated with gut microbial composition. The statistical 107 modelling results in a panel of spectral signals that are important for class discrimination (e.g. 108 treatment group vs. control patients). Signal or feature identification can be challenging in 109 global metabolic profiling. There are many publically available databases such as human metabolome database ¹⁴ and METLIN ¹⁵, software including Chenomx NMR Suite (Chenomx 110 Inc.) and AMIX (Bruker) and published literature sources, which can assist in providing 111 metabolite candidates for the selected features. Statistical total correlation spectroscopy 112 (STOCSY) analysis is a statistical tool to calculate correlation between the peaks from the 113 same molecules or the same biological pathways ^{16,17}. Further analytical experiments should 114 be carried out to confirm the metabolite identification. Various two-dimensional NMR 115 116 spectroscopic experiments can be used to elucidate the connectivity of protons and carbons of the metabolites. Tandem MS/MS can be employed to obtain fragmentation patterns of the 117 selected MS features to provide sub-molecular information for metabolite identification. In the 118 case of targeted signals or metabolites at very low concentrations, solid phase extraction is 119 often used to separate the signals of interest and concentrate it up for further 2D NMR 120 experiments. In addition, metabolite candidates can be confirmed by spiking the standard 121 compounds in the original biological samples and being tested by NMR spectroscopy or 122 comparing the LC retention times and MS fragmentation patterns from the standards and the 123 124 samples. Metabolite identification is a time consuming step and is considered to be a bottle neck in the metabolic profiling approach. These metabolite identification methods are often 125 combined in order to elucidate the structure of the targeted spectral signals. Approximate 126 127 numbers of metabolites seen in different biofluids can be in the range of thousands for both urine ¹⁸ and serum¹⁹. Statistical validation can be carried out using methods such as N-fold cross validation and permutation testing, whereas biological validation remains challenging due to further requirement of knowledge of the target metabolic pathways, appropriate validation approaches and additional resources. Statistically and biologically validated output from metabolic profiling may eventually be applied to further mechanistic investigation, and clinical diagnosis and therapeutic decision making.

134 Examples of using metabolic profiling to study gut microbial functionality

135 The advancement of systems biology techniques, in particular metabolic profiling 136 (metabolomics/metabonomics) and mathematical modelling approaches, has expanded the 137 resolution at which we can study the metabolic contribution of the gut microbiota and their 138 interaction with host biochemistry. A key strength of metabolic profiling is it's holistic nature, 139 simultaneously capturing vast amounts of metabolic information without bias, surpassing the 140 need for a specific hypothesis allowing open questions to be asked. This property is ideal for studying the gut microbiota due to it's mega-variate host-specific nature and our relatively 141 142 limited understanding. Instead metabolic profiling is a hypothesis generating top-down approach that can illuminate linkages between the gut microbiota and host metabolic 143 pathways for further evaluation. 144

145 Coupling these data-rich techniques with gnotobiotic (aka germ-free or sterile) and antibiotictreated animal models has allowed these biochemical associations to be elucidated and their 146 147 relevance to health and disease to be studied. Pair-wise comparisons of the plasma metabolic phenotypes between gnotobiotic and conventionalized mice using an LC-MS and GC-MS-148 149 based approach highlighted the influential role of the gut microbiota on circulating amino acids and organic acids ²⁰. Differences were observed in the plasma levels of bioactive indole-150 151 containing metabolites derived from tryptophan such as indoxyl sulphate and indole-3propionic acid. The absence of these metabolites in the gnotobiotic animals, coupled with their 152 greater abundance of tryptophan, indicates that this tryptophan metabolism is dependent upon 153

154 the gut microbiota. Certain bacteria possess tryptophanase activity (a deamination of the amino acid) and can break down dietary tryptophan to indole. This molecule can be absorbed 155 from the gut and metabolized in the liver to indoxyl before being sulphated to indoxyl-sulphate. 156 Indole can also be further processed by a different set of intestinal bacteria to the antioxidant 157 158 indole-3-propionic acid. The plasma of gnotobiotic animals also contained greater amounts of the amino acid tyrosine while the conventional plasma contained greater amounts of the 159 microbial-host co-metabolite 4-cresyl-sulphate. Intestinal bacteria have been shown to 160 161 metabolize dietary tyrosine to 4-cresol, which upon absorption from the gut is sulphated in the 162 liver to 4-cresyl sulphate (p-cresyl sulphate). These findings demonstrate the influence of the 163 gut microbiota on the bioavailability of dietary amino acids, precursors for a range of essential bioactive metabolites. 164

Similarly, a ¹H NMR spectroscopy-based metabonomic approach was used to characterize 165 the changes in the urinary metabolic profiles of gnotobiotic rats during 21 days of microbial 166 colonization ²¹. Here, the acquisition of the gut microbiota was accompanied by marked 167 168 changes in the urinary biochemical profile. Elevations were noted in the excretion of hippurate, phenylacetylglycine, and 3- and 4-hydroxyphenylpropionic acid (3-HPPA, 4-HPPA). These are 169 microbial-host co-metabolites that result from the microbial metabolism of dietary components. 170 171 Phenylacetylglycine arises from the bacterial metabolism of the amino acid phenylalanine to 172 phenylacetate, which is conjugated with glycine in the rat liver to form phenylacetylglycine and 173 with glutamine in the human liver to form phenylacetylglutamine. Hippurate is the glycine conjugate of benzoic acid, which can be derived from the bacterial metabolism of 174 175 phenylalanine, chlorogenic acid and catechins. These molecules can be obtained from a range 176 of polyphenolic compounds found in dietary components such as fruit, vegetables, tea and 177 coffee ²². Interestingly, in a large-scale metabolic phenotyping study in humans from China, Japan, United Kingdom and the United States, hippurate excretion was found to be inversely 178 associated with blood pressure, a major risk factor for cardiovascular disease ²³. Formate, a 179 product of gut microbial fibre fermentation, was also inversely associated with blood pressure. 180

181 Another metabonomic study characterized the systemic metabolic adaptation to gut colonization in gnotobiotic mice ²⁴. Following 5 days of conventionalization, the metabolic 182 strategy of the liver shifted from glycogenesis to lipogenesis. This observation was consistent 183 with another study combining a transcriptomic and metabonomic approach to study metabolic 184 185 response to colonization in the mouse jejunum. Here, two days of colonization resulted in the suppression of lipid catabolism (e.g. β -oxidation) in the jejunum and activation of anabolic 186 pathways (e.g. lipogenesis, nucleotide synthesis and amino acid synthesis)²⁵. Such 187 biochemical reorientations occurred in parallel to a rapid increase in body weight. These 188 189 observations indicate the intimate biochemical relationship between the gut microbiota and 190 host and how the host metabolic phenotype is shaped with the development of the gut microbiota. 191

192 Antibiotic-treated animal models offer another tool for investigating microbial-host interactions. Gnotobiotic animals differ phenotypically from conventional animals raised in the presence of 193 bacteria. Gnotobiotic animals have a reduced body weight, a lower metabolic rate, 194 195 underdeveloped gut structure and absorptive capacity, and an immature immune system and 196 as such can obscure the interpretation of results. Administering antibiotics to conventionally raised animals allows the influence of the gut microbiota on host biochemistry to be studied 197 whilst preserving the conventional phenotype. This influence was demonstrated by 198 199 administering the broad-spectrum antibiotics streptomycin and penicillin in the drinking water of rats for eight days ²⁶ and in an early study vancomycin to mice ²⁷. Swann and colleague 200 201 used ¹H NMR spectroscopy to compare the urinary and faecal metabolic profiles of control, 202 antibiotic suppressed and a group undergoing recolonization (4 days of antibiotics followed by 4 days of control treatment). In this study, antibiotic-induced suppression of the intestinal 203 204 microbiota reduced the urinary excretion of hippurate, phenylpropionic acid, phenylacetylglycine, indoxyl-sulphate, trimethylamine-N-oxide (TMAO) and the short chain 205 fatty acid (SCFA), acetate. The excretion of the amino acids taurine and glycine, and the TCA 206 cycle intermediates, citrate, 2-oxoglutarate, and fumarate was increased following microbial 207

208 attenuation. In addition, all the SCFA (acetate, butyrate, propionate) were reduced in the faeces of the antibiotic-treated rats. SCFA arise from the bacterial fermentation of 209 carbohydrates, including non-digestible polysaccharides. As these products provide a 210 significant energy source for the host, this represents a key function of the gut microbiota 211 212 salvaging energy from the diet. A human study by Claesson et al. ²⁸ correlated faecal metabolic and microbial profiles to highlight a putative statistical association between butyrate and the 213 presence of Ruminococcus or Butyricicoccus. Microbial and metabolic profiling of the 214 215 recolonizing animals revealed a cage-dependent bacterial recolonization. This differnece was 216 mirrored by cage-dependent differences in the metabolic signatures. This highlights the 217 potential for environmental pressures to shape the gut bacterial re-establishment postantibiotic therapy with downstream implications on the metabolic state of the host. 218

219 In addition to global profiling of low molecular weight metabolites, we can also target specific 220 molecules or families of molecules, for example, bile acids and eicosanoids. Targeted profiling of the bile acid signature enables a detailed overview of the enterohepatic circulation to be 221 222 gained and the influence of the gut microbiota to be studied ¹³. The circulating and hepatic bile acid pool contains more than 30 known bile acids and the gut microbiota is responsible for 223 driving the majority of this diversity ²⁹. Primary bile acids (cholic acid and chenodeoxycholic 224 225 acid) are synthesized in the liver from cholesterol and are conjugated with either taurine or 226 glycine before secretion into the bile. Upon ingestion of a meal, bile acids stored in the gall 227 bladder are expelled from the gall bladder into the small intestine and although the majority 228 are actively absorbed in the small intestine a minor amount (1-5%; 200-800 mg daily in 229 humans) reaches the colon. It is here that bile acids are modified by the resident microbiota. 230 Many bacteria possess bile salt hydrolase (BSH) enzymes that deconjugate the bile acid from 231 its amino acid. Once deconjugated further bacterial modifications can occur such as dehydroxylation giving rise to secondary bile acids such as deoxycholic acid and lithocholic 232 acid. Modified bile acids can be absorbed and recycled to the liver where they are 233 reconjugated and secreted into the bile. This absorption forms the enterohepatic circulation 234

235 whereby molecules are shuttled between the host liver and the microbiome. While bile acids have a key role in lipid digestion and absorption they are now also recognized as important 236 signalling molecules serving as ligands for the nuclear receptor; farnesoid X receptor (FXR), 237 and the plasma membrane bound G protein-coupled receptor, TGR5^{30,31}. Through binding to 238 these receptors bile acids can regulate genes involved in lipid ³²⁻³⁴ and glucose metabolism 239 ^{35,36} and energy homeostasis ³⁷. Using a parallel transcriptomic and metabonomic approach 240 the influence of the gut microbiota on the enterohepatic circulation and its signalling capacity 241 was studied ³⁸. An LC-MS based approach identified pronounced variation in the bile acid 242 243 signatures of conventional and gnotobiotic rats with similar modulations induced by antibiotic 244 treatment. The absence or attenuation of the gut microbiota shifted the bile acid signature to 245 one dominated by taurine-conjugated bile acids and strikingly reduced the diversity of the bile 246 acid pool. Such modulations impacted on the signalling function of the bile acid profile with 247 significant alterations in the expression of genes and pathways regulated by bile acids. In addition to being measured in the blood and liver, bile acids were also measured in tissues 248 249 outside of the enterohepatic circulation (kidney, heart) indicating a broader signalling role of these microbial-host co-metabolites. 250

Metabolic profiling strategies applied to human studies have also expanded our understanding 251 252 of the gut microbial contribution to host digestion and metabolism. This is well illustrated by 253 the microbial metabolism of dietary choline to trimethylamine (TMA). Choline is predominantly derived from phosphatidylcholine found in animal sources in the diet. The microbial 254 metabolism of choline involves the cleavage of the C-N bond to liberate TMA and 255 256 acetaldehyde. While acetaldehyde undergoes further microbial metabolism to ethanol, TMA 257 is absorbed from the gut and oxidized in the liver to form trimethylamine-N-oxide (TMAO) by 258 the flavin-containing monooxygenase 3 (FMO3) enzyme. TMA can also be demethylated to dimethylamine both endogenously and by the gut microbiota (PMID: 4091797). Microbial 259 processing of choline is well established ³⁹ and TMA and TMAO have been previously 260 observed in biofluids from gnotobiotic and antibiotic-treated rodents ^{21,26,40}. However, recent 261

262 work in humans has linked this activity to increased cardiovascular disease (CVD) risk. In a global metabolic profiling study in humans, Wang et al.⁴¹ found that three plasma metabolites 263 were predictive of CVD, choline, its metabolite betaine, and TMAO. The role of these 264 metabolites in CVD risk was investigated by feeding them individually to mice. Both choline 265 266 and TMAO were found to promote atherosclerosis and all three metabolites up-regulated the expression of macrophage scavenger receptors known to contribute to the atherosclerotic 267 process. The essential role of the gut microbiota in potentiating the bioactivity of choline 268 269 through TMA production was confirmed using gnotobiotic mice. In a metabolic profiling study, 270 microbial choline metabolism has also been shown to exacerbate non-alcoholic fatty liver disease (NAFLD), a condition caused by choline deficiency, in mice ⁴². 271

272 The potential for the gut microbiota to influence host drug metabolism has been demonstrated 273 in a human study characterising the metabolic fate of paracetamol/acetaminophen ⁴³. The metabolic output of the gut microbiota, specifically 4-cresol, was found to influence the phase 274 II detoxification of this widely used analgesic. 4-cresol has toxic properties and requires 275 276 detoxification by the host. The primary route of this detoxification is sulfation (both in the gastrointestinal tract and in the liver) before excretion in the urine. This is also the preferred 277 route of detoxification for acetaminophen and both molecules are sulphated by the same 278 human cytosolic sulfotransferase, SULT1A1. As these two molecules compete for binding 279 280 sites as well as for sulphate, the 4-cresol output of the gut microbiota can influence the ability 281 of the host to sulphate acetaminophen. Alternative routes of detoxification including glucuronidation and phase I metabolism by the cytochrome P450 enzymes. Importantly, 282 phase I metabolism results in the generation of the toxic intermediate, N-acetyl-p-283 284 benzoquinone imine (NAPQI). In this study, individuals excreting high amounts of 4-cresol 285 before receiving a standard dose of acetaminophen were found to excrete lower amounts of acetaminophen sulphate and higher amounts of acetaminophen-glucuronide. Such an 286 observation is not limited to acetaminophen and many xenobiotics are detoxified via sulfation. 287 Interestingly, using a molecular epidemiology approach we have also observed 4-cresyl 288

289 sulphate excretion to be positively correlated with age. This observation was found in both a US and Taiwanese populations suggesting that this age-associated change in the metabolic 290 functionality of the gut microbiome is independent of diet and cultural influences. This data 291 has particular relevance given the greater use of drug therapy with aging ⁴⁴. The influence of 292 293 the gut microbiota on idiosyncratic drug responses has also been demonstrated in a rodent study with the hepatotoxin, hydrazine ⁴⁰. In this metabolic profiling study the protective effect 294 of an established microbiome was demonstrated in rats with gnotobiotic animals showing a 295 296 marked toxic response to a typically sub-toxic dose. These studies demonstrate the potential 297 of using a global metabolic profiling approach to characterize the metabolic functionality of the gut microbiota to predict the efficacy and safety of orally administered xenobiotics. This 298 299 represents a step towards a precision medicine approach tailoring pharmacological 300 interventions to the metabolic status of the complete biological system including contributions 301 from the host genome and the microbiome.

302 Future directions

To maximise the potential of metabonomic approaches and using them for defining the role which microbes play in maintaining health and driving disease we predict that the follow areas of research will need to be developed.

- High throughput profiling of cellular responses to metabolites, currently we do not have
 platform which allow us to measure the responses of different cell types, e.g. colonocytes
 or hepatocytes to doses or combinations of metabolites.
- A metabolic lexicon of bacteria who makes what and from what substrate. The range of
 metabolites that different microbes make and from what, so we can predict how changes
 in the composition of the microbiota affects the metabonome is needed.
- The interactions between bacteria and their combined impact on the host. Many studies look at single organisms, but we are far from understanding how the microbes interact with each other and how this network affects the host via the metabolite axis.

315


316 Conclusions

To understand how humans function now needs a systems based approach which incorporates the microbiome and its associated metabonome. The metabolic super-highway is the key avenue along which microbes influence the host's metabolism and physiology. In order to understand humans we must start to understand and incorporate this knowledge into our model of the biology otherwise we will still be scrabbling around for explanations for disease for many years to come.

324 Figure Legends

Figure 1. O-PLS regression analyses of faecal water from a rat model of bariatric surgery against relative suspension growth values obtained from a 24-h treatment of L5178Y cells. Peaks pointing upward in the loadings plots represent metabolites which are positively correlated to the cell growth and *vice versa*. Red peaks reach a significance level of p < 0.005. Keys: GABA, gamma-aminobutyric acid; IS, indoxyl sulfate; PAG, phenylacetylglycine; pcresyl sulf, p-cresyl sulfate; p-cresyl glu, p-cresyl glucuronide. (Reproduced with permission from ⁴⁵ and modified).

332



333

335 **References**

- Tlaskalova-Hogenova H, Vannucci L, Klimesova K, Stepankova R, Krizan J, Kverka M.
 Microbiome and colorectal carcinoma: insights from germ-free and conventional animal
 models. *Cancer J*. 2014;20(3):217-224.
- Marcobal A, Kashyap PC, Nelson TA, et al. A metabolomic view of how the human gut
 microbiota impacts the host metabolome using humanized and gnotobiotic mice. *ISME J.* 2013;7(10):1933-1943.
- 342 3. Gordon HA, Wostmann BS, Bruckner-Kardoss E. Effects of Microbial Flora on Cardiac
 343 Output and Other Elements of Blood Circulation. *Proc Soc Exp Biol Med.* 1963;114:301344 304.
- Quevauviller A, Laroche MJ, Cottart A, Sacquet E, Charlier E. [Anesthetic Activity and
 Comparative Metabolism of Hexobarbital in the Germ-Free and Conventional Mouse]. *Ann Pharm Fr.* 1964;22:339-344.
- Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of
 mammals to their commensal intestinal microbiota. *Semin Immunol.* 2007;19(2):59-69.
- Gratton J, Phetcharaburanin J, Mullish BH, et al. Optimized Sample Handling Strategy for
 Metabolic Profiling of Human Feces. *Anal Chem.* 2016;88(9):4661-4668.
- 352 7. Siddiqui NY, DuBois LG, St John-Williams L, et al. Optimizing Urine Processing Protocols
 353 for Protein and Metabolite Detection. *J Proteomics Bioinform.* 2015;2015(Suppl 14).
- 8. Teahan O, Gamble S, Holmes E, et al. Impact of analytical bias in metabonomic studies of
 human blood serum and plasma. *Anal Chem.* 2006;78(13):4307-4318.
- Holmes E, Wijeyesekera A, Taylor-Robinson SD, Nicholson JK. The promise of metabolic
 phenotyping in gastroenterology and hepatology. *Nat Rev Gastroenterol Hepatol.* 2015;12(8):458-471.
- Beckonert O, Keun HC, Ebbels TM, et al. Metabolic profiling, metabolomic and
 metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue
 extracts. *Nat Protoc.* 2007;2(11):2692-2703.

- Want EJ, Masson P, Michopoulos F, et al. Global metabolic profiling of animal and
 human tissues via UPLC-MS. *Nat Protoc.* 2013;8(1):17-32.
- Want EJ, Wilson ID, Gika H, et al. Global metabolic profiling procedures for urine using
 UPLC-MS. *Nat Protoc.* 2010;5(6):1005-1018.
- Sarafian MH, Lewis MR, Pechlivanis A, et al. Bile acid profiling and quantification in
 biofluids using ultra-performance liquid chromatography tandem mass spectrometry. *Anal Chem.* 2015;87(19):9662-9670.
- 369 14. Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0--The Human Metabolome Database
 370 in 2013. *Nucleic Acids Res.* 2013;41(Database issue):D801-807.
- 371 15. Smith CA, O'Maille G, Want EJ, et al. METLIN: a metabolite mass spectral database.
 372 *Ther Drug Monit.* 2005;27(6):747-751.
- 16. Cloarec O, Dumas ME, Craig A, et al. Statistical total correlation spectroscopy: an
 exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. *Anal Chem.* 2005;77(5):1282-1289.
- 17. Robinette SL, Lindon JC, Nicholson JK. Statistical spectroscopic tools for biomarker
 discovery and systems medicine. *Anal Chem.* 2013;85(11):5297-5303.
- 378 18. Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome. *PLoS One.*379 2013;8(9):e73076.
- 19. Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. *PLoS One.*2011;6(2):e16957.
- Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut
 microflora on mammalian blood metabolites. *Proc Natl Acad Sci U S A*. 2009;106(10):36983703.
- Nicholls AW, Mortishire-Smith RJ, Nicholson JK. NMR spectroscopic-based
 metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. *Chem Res Toxicol.* 2003;16(11):1395-1404.
- Lees HJ, Swann JR, Wilson ID, Nicholson JK, Holmes E. Hippurate: the natural history
 of a mammalian-microbial cometabolite. *J Proteome Res.* 2013;12(4):1527-1546.

- 390 23. Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its
 391 association with diet and blood pressure. *Nature*. 2008;453(7193):396-400.
- Claus SP, Ellero SL, Berger B, et al. Colonization-induced host-gut microbial metabolic
 interaction. *MBio.* 2011;2(2):e00271-00210.
- El Aidy S, Merrifield CA, Derrien M, et al. The gut microbiota elicits a profound
 metabolic reorientation in the mouse jejunal mucosa during conventionalisation. *Gut.* 2013;62(9):1306-1314.
- 397 26. Swann JR, Tuohy KM, Lindfors P, et al. Variation in antibiotic-induced microbial
 398 recolonization impacts on the host metabolic phenotypes of rats. *J Proteome Res.*399 2011;10(8):3590-3603.
- Yap IK, Li JV, Saric J, et al. Metabonomic and microbiological analysis of the dynamic
 effect of vancomycin-induced gut microbiota modification in the mouse. *J Proteome Res.*2008;7(9):3718-3728.
- 403 28. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with
 404 diet and health in the elderly. *Nature*. 2012;488(7410):178-184.
- 405 29. Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of
 406 circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS407 validated method. *J Lipid Res.* 2012;53(10):2231-2241.
- 408 30. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. *EMBO J.*409 2006;25(7):1419-1425.
- 410 31. Eloranta JJ, Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis.
 411 *Physiology (Bethesda).* 2008;23:286-295.
- 412 32. Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R. Bile acid reduces the
 413 secretion of very low density lipoprotein by repressing microsomal triglyceride transfer
 414 protein gene expression mediated by hepatocyte nuclear factor-4. *J Biol Chem.*415 2004;279(44):45685-45692.

416 33. Kast HR, Nguyen CM, Sinal CJ, et al. Farnesoid X-activated receptor induces
417 apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels
418 to bile acids. *Mol Endocrinol.* 2001;15(10):1720-1728.

419 34. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a
420 pathway involving FXR, SHP, and SREBP-1c. *J Clin Invest.* 2004;113(10):1408-1418.

421 35. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1

- 422 secretion through TGR5 in a murine enteroendocrine cell line STC-1. *Biochem Biophys*423 *Res Commun.* 2005;329(1):386-390.
- 424 36. Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism
 425 by the farnesoid X receptor. *Endocrinology*. 2005;146(3):984-991.
- 426 37. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by 427 promoting intracellular thyroid hormone activation. *Nature.* 2006;439(7075):484-489.
- 38. Swann JR, Want EJ, Geier FM, et al. Systemic gut microbial modulation of bile acid
 metabolism in host tissue compartments. *Proc Natl Acad Sci U S A.* 2011;108 Suppl
 1:4523-4530.
- 431 39. Asatoor AM, Simenhoff ML. The origin of urinary dimethylamine. *Biochim Biophys Acta*.
 432 1965;111(2):384-392.
- 43. Swann J, Wang Y, Abecia L, et al. Gut microbiome modulates the toxicity of hydrazine:
 434 a metabonomic study. *Mol Biosyst.* 2009;5(4):351-355.
- 435 41. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine
 436 promotes cardiovascular disease. *Nature*. 2011;472(7341):57-63.
- 437 42. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut
 438 microbiota to fatty liver phenotype in insulin-resistant mice. *Proc Natl Acad Sci U S A*.
 439 2006;103(33):12511-12516.
- 43. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic
 identification of a significant host-microbiome metabolic interaction affecting human drug
 metabolism. *Proc Natl Acad Sci U S A.* 2009;106(34):14728-14733.

- 44. Swann JR, Spagou K, Lewis M, et al. Microbial-mammalian cometabolites dominate
 the age-associated urinary metabolic phenotype in Taiwanese and American populations. *J Proteome Res.* 2013;12(7):3166-3180.
- 446 45. Li JV, Reshat R, Wu Q, et al. Experimental bariatric surgery in rats generates a
- 447 cytotoxic chemical environment in the gut contents. *Front Microbiol.* 2011;2:183.